SenzaGen AB
@SenzagenAb
Followers
468
Following
318
Media
328
Statuses
555
SenzaGen is seizing high-growth opportunities in the in vitro toxicology testing market, driven by the shift from animal testing to human-relevant solutions.
Lund, Sverige
Joined April 2016
SenzaGen bidrar till säkrare produkter i samhället - utan att offra miljontals djur. Den 10 november berättar vi mer på vår kapitalmarknadsdag i Stockholm och ni är självklart välkomna. Anmäl dig på vår hemsida! @dagligutdelning
instagram.com
0
0
0
SenzaGen has received a new follow-up order worth approx. 1.0 MSEK for GARD®. The continued trust from this major U.S. pharmaceutical company confirms that our unique GARD® technology, together with our commercial strategy, is delivering results. https://t.co/4haVTYseqk
0
0
2
CEO on Q2 2025: A strong starting position for the coming quarters: We enter H2 with a stronger order book, costs under control, and expanded GARD® approval supporting growth and margins.
senzagen.com
Message from the CEO
0
0
1
Important move by the FDA: phasing out animal testing in drug development. As a pioneer in innovative testing technologies based on machine-learning, genomics, and organoids, SenzaGen sees strengthened potential in the pharma sector. https://t.co/4ruCGs12dw
0
0
0
Take part of our 2024 Annual Report! CEO Peter Nählstedt reflects on strong customer demand, solid performance, cash position, ongoing growth projects, and the journey ahead as we build SenzaGen into a leader in non-animal testing. https://t.co/T1yTS0TGQB
0
0
0
SenzaGen secures new important orders with an expanded customer offering. EpiSensA complements GARD®skin and strengthens our regulatory testing portfolio. First CRO to market, first to secure orders – proof of trust and demand. https://t.co/IyIcZw4t03
0
0
0
Västra Hamnen besöks av Peter Nählstedt, VD på SenzaGen. Lyssna till ett samtal om tillväxt, globala marknadsledande kunder och in vitro-tester som inte bara utläser toxicitet utan även effekt. #VästraHamnenMöter #SenzaGen $SENZA https://t.co/fxadtR5vvd
0
3
8
Redeye interviewed the CEO of SenzaGen, Peter Nählstedt, about the company's recently released Q3 2024 report. $SENZA https://t.co/whlRT9Fsmm
0
1
1
Read @exxonmobil's new article on skin sensitization hazard challenges for difficult-to-test substances with conflicting or low-confidence data, where GARDskin data on UVCBs and hydrophobic substances offer insights for the integrated hazard assessment. https://t.co/Qj3Ck9czfv
pubmed.ncbi.nlm.nih.gov
Difficult to test substances, including poorly soluble, mildly irritating, or UVCBs (unknown or variable composition complex reaction products or biological materials), producing weak or borderline...
0
0
3
SenzaGen is on a growth path. Watch CEO Peter Nählstedt present the company at BioStock Life Science Summit 2023. #salesgrowth #investorpitch #ceo #biostock #invitro #genomics #machinelearning
https://t.co/b5W9dEjxVT
0
0
5
Today at 10.40 CEO Peter Nählstedt presents at Redeye Medtech Event. Follow the live broadcast at https://t.co/P15pg70idu
0
0
3
Redeye endorses SenzaGen's new GARDskin order of SEK1m from a new customer within the chemical industry. Our analyst gives his initial comment: $SENZA https://t.co/stWjShw3IL
0
2
2
Redeye comments on SenzaGen's Q3 2022 sales update, with total sales of SEK9m: $SENZA https://t.co/OGeFOzru2A
redeye.se
Redeye comments on SenzaGen’s Q3 sales update with total sales of SEK9m. We endorse that the company continues to grow and believe in a stronger Q4. The sales update does not render any changes in ou
0
1
0
We have been selected to test substances for a new customer, a world leader in the chemicals industry. This serves as further confirmation of interest in GARD®skin’s unique capability to be used for and generate more data on difficult-to-test substances. https://t.co/UI5X6MYjL3
0
0
3
Redeye has interviewed SenzaGen's CEO, Peter Nählstedt. We discuss the OECD approval for GARDskin that the company received last week: $SENZA https://t.co/Zs6yqNVrSM
0
1
2
Redeye endorses the news that SenzaGen has received its largest order so far, with a value of SEK 4.2m: $SENZA https://t.co/KFzXj35zUE
0
1
3
Redeye recently initiated coverage of SenzaGen, a Swedish Medtech company active in non-animal testing across several major industries. We have interviewed our analyst covering the company: $SENZA https://t.co/AujmB1IBsg
0
1
1
Se klippet nedan – hos Redeye AB igår berättade VD Peter Nählstedt om den starka försäljningsutvecklingen under Q1 då bolagets försäljning ökade med drygt 370 procent till 9,0 MSEK genom mycket stark organisk och förvärvsdriven tillväxt. https://t.co/H3uqPIc0VD
0
0
0
We are very proud to continue our collaboration with Research Institute for Fragrance Materials, Inc. (RIFM). RIFM’s continued trust in us affirms their appreciation of the many application areas that our GARD® technology offers. https://t.co/tCn22L7SFn
#invitro #Genomics
senzagen.com
SenzaGen will continue its collaboration with the Research Institute for Fragrance Materials (RIFM) on non-animal photosensitization testing. The new grant provided by RIFM will add SEK 1.5 million...
0
1
2
Se klippet nedan – hos Redeye igår berättade VD Peter Nählstedt om den nya strategin som bolaget sjösatt under 2021, förvärvet av VitroScreen samt den senaste utvecklingen i bolaget. https://t.co/C4A7YXI7Pk
0
0
1